Malaysia’s Bioeconomy Corp. Senior VP Visits Healthcare+ Expo Taiwan, Accelerates Clinical Innovation and Traditional Medicine Advancement

Malaysia’s biotech ascent has been years in the making. Since 2020, government policy and private investment have driven breakthroughs in cell and gene therapy, biopharmaceuticals, precision medicine, medical devices, and herbal remedies. In particular, Malaysia’s unique demographic-over 50 indigenous groups among its 32.7 million people-provides valuable clinical trial samples and diverse data, making the country a model for neighboring nations.

With eight years of experience in herbal research and a focus on key pharmaceutical technologies like supercritical fluid extraction, Soeraya's background underscores the mutual interest in advancing the pharmaceutical sector. It's understood that Taiwan's mature capabilities in traditional medicine innovation are a significant draw for Malaysia, fostering strong expectations for substantive collaboration in this field.

Official data show Malaysia’s biotech industry is projected to grow from $35.7 billion in 2020 to $43.1 billion by 2030, with an annual growth rate of 15%. The Bioeconomy Development Corporation, which oversees nearly 600 biotech companies spanning agriculture, healthcare, and industry, has set clear goals: cultivate at least three unicorns and enable 30% of companies to have export capacity by 2030, while raising the sector’s GDP contribution to 5%. Some local firms are already preparing for a Nasdaq listing, underlining the sector’s transformation momentum.

Meanwhile, Taiwan’s biotech sector continues to gain international traction across new drug development, cell and gene therapy, biologics, and medical big data analytics. Government support, integrated biomedical clusters, and cross-institutional clinical trial collaborations have created one of Asia’s most complete biotech ecosystems.